https://pf-04418948antagonist.....com/digital-truth-in
We further evaluated this PDX model by experimental chemotherapy, demonstrating that this HCC PDX design was sensitive to sorafenib treatment. Further, the possibility of normal killer cell-based immunotherapy for HCC had been tested using this model. We discovered that NK92 cells successfully suppressed the tumefaction growth in vivo and prolonged the survival time of HCC-bearing PDX mice. This study shows that HCC PDX model is a good platform to testify the efficacy of preclinical chemotherapy and i
Curtir
Comentario
Compartilhar
